Ajinomoto Bio-Pharma Services
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ajinomoto Bio-Pharma Services
The company is developing a next-generation antibody for prevention of COVID-19 that targets highly conserved regions of the SARS-CoV-2 virus and thus may be able to overcome resistance.
AbbVie’s migraine prophylactic and GSK’s treatment for anemia associated with chronic kidney disease were both recommended for pan-EU marketing approval by the European Medicines Agency this week.
MSD/Ridgeback Biotherapeutics’ COVID-19 treatment Lagevrio is among the products that are up for an opinion this week from the European Medicines Agency on whether they should be recommended for use across the EU.
Concentra's unsolicited bid for Atea is the latest proof that promising but financially strapped biotechs that are trading below cash are prime M&A targets.
- Contract Research, Toxicology Testing-CRO
- Research, Analytical Equipment & Supplies
- Contract Manufacturing Organization
- Other Names / Subsidiaries
- Althea Technologies, Inc.
- Ajinomoto Pharmaceuticals Co., Ltd.
- EA Pharma Co., Ltd.
- Granules OmniChem Private Limited
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.